2024-11-07 - Analysis Report
## Johnson & Johnson (JNJ) Stock Analysis Report

**1. Performance Comparison:**

Johnson & Johnson (JNJ) is a multinational pharmaceutical, medical devices, and consumer packaged goods company. The company has underperformed the S&P 500 (VOO) over the past period, with a cumulative return of 32.0% compared to the S&P 500's 134.06%. This results in a relative underperformance of -102.06%, which represents the 3.1st percentile of its historical underperformance against the S&P 500.  

**Alpha and Beta Analysis:**

The company's alpha and beta analysis indicates that JNJ has generally outperformed the market over the past years. Its alpha, representing the outperformance, has been positive in most periods, except for 2017-2019 and 2018-2020. However, its beta, measuring the stock's volatility relative to the market, has been consistently below 1, suggesting a lower level of volatility than the overall market. 

**2. Recent Price Movement:**

* **Closing Price:** $158.35 (Last-market: $157.88)
* **5-Day Moving Average:** $159.44
* **20-Day Moving Average:** $161.89
* **60-Day Moving Average:** $162.65

The stock is currently trading below its 5, 20, and 60-day moving averages, indicating a short-term downtrend.

**3. Technical Indicators:**

* **RSI:** 32.47 (below 30, suggesting oversold conditions)
* **PPO:** -0.31 (below zero, indicating a bearish sentiment)
* **Relative Divergence:** -1.75 (negative, indicating a short-term downtrend)
* **Expected Return:** 0.0% (The expected return indicates that the stock is anticipated to perform in line with the S&P 500 over the long term (2+ years) based on current market conditions and analysis.)

**4. Recent Earnings & Outlook:**

| Date         | EPS    | Revenue      |
|--------------|--------|---------------|
| 2024-10-23 | $1.12  | $22.47 B     |
| 2024-07-25 | $1.95  | $22.45 B     |
| 2024-05-01 | $1.35  | $21.38 B     |
| 2024-02-16 | $1.68  | $21.39 B     |
| 2023-10-27 | $10.32 | $21.35 B     |

Johnson & Johnson's recent earnings have shown a mixed performance. While the company's revenues have remained relatively stable, EPS has fluctuated. Notably, the latest reported EPS of $1.12 fell short of analyst estimates, possibly contributing to the recent price decline.

**5. Financial Data:**

**1) Revenue and Profitability:**

| Quarter       | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2024-09-30 | $22.47B  | 69.01%       |
| 2024-06-30 | $22.45B  | 69.40%       |
| 2024-03-31 | $21.38B  | 69.55%       |
| 2023-12-31 | $21.39B  | 68.23%       |
| 2023-09-30 | $21.35B  | 69.06%       |

JNJ has maintained strong profitability levels with consistent high profit margins. Revenue has remained relatively steady, demonstrating the company's stable financial performance.

**2) Capital and Profitability:**

| Quarter       | Equity    | ROE    |
|--------------|-----------|--------|
| 2024-09-30 | $70.16B  | 3.84%  |
| 2024-06-30 | $71.54B  | 6.55%  |
| 2024-03-31 | $70.02B  | 4.65%  |
| 2023-12-31 | $68.77B  | 5.89%  |
| 2023-09-30 | $71.23B  | 36.54% |

The company's ROE has been fluctuating but generally demonstrates a healthy level of profitability. 

**6. News & Recent Issues:**

* **Recent Earnings:**  The recent earnings report released on October 23, 2024, showed a decline in EPS compared to analysts' expectations. This has led to a short-term dip in the stock price.
* **Recent Market Outlook:** The stock is currently facing some headwinds due to the recent earnings miss and the overall market uncertainty.
* **Analyst Opinions and Performance Highlights:** While the stock has underperformed the S&P 500 recently, many analysts continue to maintain a positive outlook for JNJ's long-term prospects, citing its strong financial position and dividend record.

**7. Overall Analysis:**

Johnson & Johnson is a well-established and financially stable company, with a history of strong profitability and dividend payments. The stock has recently underperformed the S&P 500, mainly due to the recent earnings miss and the broader market volatility. Despite this, the company's long-term prospects remain positive, and many analysts continue to recommend JNJ for long-term investors. However, investors should consider the current market uncertainty and be prepared for short-term volatility before investing in the stock. 
